Abstract
Antisense oligonucleotides (ASOs) have promising therapeutic potential in oncotherapy. However, low stability and efficacy limit their application in the clinic. Cationic liposomes have been investigated as delivery vehicles for ASOs. Here, we report the synthesis and evaluation of an ASO delivery vehicle comprising cationic liposomes incorporating fatty acid-modified polyethylenimine. An oleic acid derivative of branched polyethylenimine (PEI-OA) and a linoleic acid derivative of branched polyethylenimine (PEI-LA) were synthesized and incorporated into liposomes. The PEImodified liposomes were synthesized by an ethanol injection method with composition of PEI-modified lipid/Chol/TPGS. The properties of these liposomes, including cytotoxicity, cellular uptake, ASO target silencing activity, based on mRNA and protein downregulation, were investigated. LOR-2501, an ASOs targeting ribonucleotide reductase R1 subunit (R1) was used as the therapeutic cargo. The PEI-modified liposomes showed relatively compact particle size and excellent colloidal stability for at least 25 days. PEI-modified liposomes effectively delivered LOR-2501 into KB cells and efficiently induced down-regulation of R1 mRNA and protein. Compared with regular cationic liposomes, PEI-modified liposomes was more effective, reducing R1 mRNA and protein by ~10%.
Keywords: Antisense oligonucleotide delivery, cancer, cationic liposomes, polyethylenimine.
Current Pharmaceutical Biotechnology
Title:Enhanced Antisense Oligonucleotide Delivery Using Cationic Liposomes Incorporating Fatty Acid-Modified Polyethylenimine
Volume: 15 Issue: 9
Author(s): Zhihua Guo, Yujing Li, Yige Fu, Tianqi Guo, Xin Li, Shuang Yang and Jing Xie
Affiliation:
Keywords: Antisense oligonucleotide delivery, cancer, cationic liposomes, polyethylenimine.
Abstract: Antisense oligonucleotides (ASOs) have promising therapeutic potential in oncotherapy. However, low stability and efficacy limit their application in the clinic. Cationic liposomes have been investigated as delivery vehicles for ASOs. Here, we report the synthesis and evaluation of an ASO delivery vehicle comprising cationic liposomes incorporating fatty acid-modified polyethylenimine. An oleic acid derivative of branched polyethylenimine (PEI-OA) and a linoleic acid derivative of branched polyethylenimine (PEI-LA) were synthesized and incorporated into liposomes. The PEImodified liposomes were synthesized by an ethanol injection method with composition of PEI-modified lipid/Chol/TPGS. The properties of these liposomes, including cytotoxicity, cellular uptake, ASO target silencing activity, based on mRNA and protein downregulation, were investigated. LOR-2501, an ASOs targeting ribonucleotide reductase R1 subunit (R1) was used as the therapeutic cargo. The PEI-modified liposomes showed relatively compact particle size and excellent colloidal stability for at least 25 days. PEI-modified liposomes effectively delivered LOR-2501 into KB cells and efficiently induced down-regulation of R1 mRNA and protein. Compared with regular cationic liposomes, PEI-modified liposomes was more effective, reducing R1 mRNA and protein by ~10%.
Export Options
About this article
Cite this article as:
Guo Zhihua, Li Yujing, Fu Yige, Guo Tianqi, Li Xin, Yang Shuang and Xie Jing, Enhanced Antisense Oligonucleotide Delivery Using Cationic Liposomes Incorporating Fatty Acid-Modified Polyethylenimine, Current Pharmaceutical Biotechnology 2014; 15 (9) . https://dx.doi.org/10.2174/138920101509141107122927
DOI https://dx.doi.org/10.2174/138920101509141107122927 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
HDAC Inhibitors-New Generation of Target Specific Treatment
Mini-Reviews in Medicinal Chemistry Iron Oxide Nanoparticles: An Insight into their Biomedical Applications
Current Medicinal Chemistry Patent Selections
Recent Patents on Biomarkers Role of Physician Gender in the Quality of Care of Cardiometabolic Diseases
Current Pharmaceutical Design Cytokine Production Induced by Marine Algae Lectins in BALB/c Mice Splenocytes
Protein & Peptide Letters Targeting MDM2 and MDMX in Retinoblastoma
Current Cancer Drug Targets Can an Apple a Day Keep the Doctor Away?
Current Pharmaceutical Design Inhibitors of 17β-Hydroxysteroid Dehydrogenases
Current Medicinal Chemistry Ethosomal Hydrogel of Raloxifene HCl: Statistical Optimization & Ex Vivo Permeability Evaluation Across Microporated Pig Ear Skin
Current Drug Delivery Nitric Oxide: Friendly Rivalry in Tuberculosis
Current Signal Transduction Therapy Exploring AT2R and its Polymorphism in Different Diseases: An Approach to Develop AT2R as a Drug Target beyond Hypertension
Current Drug Targets Role of NF-κB and NF-κB-regulated Gene Products in Chemoresistance and Radioresistance
Current Cancer Therapy Reviews Clinical Experience with Antiangiogenic Therapy in Leukemia
Current Cancer Drug Targets Low Dose Aspirin, COX-Inhibition and Chemoprevention of Colorectal Cancer
Current Topics in Medicinal Chemistry An Apple Plus a Brazil Nut a Day Keeps the Doctors Away: Antioxidant Capacity of Foods and their Health Benefits
Current Pharmaceutical Design PET Imaging of Multidrug Resistance in Tumors Using 18F-Fluoropaclitaxel
Current Topics in Medicinal Chemistry The Ubiquitin-Proteasome System and Proteasome Inhibitors in Central Nervous System Diseases
Cardiovascular & Hematological Disorders-Drug Targets The Development of Inhibitors of Heparanase, a Key Enzyme Involved in Tumour Metastasis, Angiogenesis and Inflammation
Mini-Reviews in Medicinal Chemistry Inhibitors of Aldo-Keto Reductases AKR1C1-AKR1C4
Current Medicinal Chemistry New Pharmacological Approaches to the Cholinergic System: An Overview on Muscarinic Receptor Ligands and Cholinesterase Inhibitors
Recent Patents on CNS Drug Discovery (Discontinued)